Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD
Published: Thursday, Jun 22, 2017



Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

It was confirmed in a large cohort of 4000 patients with cyptogenic HCC, that one-third did not have cirrhosis, explains Jun. It was also discovered that this population presents with a later stage of disease and often with more advanced tumors.

According to Jun, this suggests that if there was better early detection, these patients might have better survival rates.
 
SELECTED
LANGUAGE


Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

It was confirmed in a large cohort of 4000 patients with cyptogenic HCC, that one-third did not have cirrhosis, explains Jun. It was also discovered that this population presents with a later stage of disease and often with more advanced tumors.

According to Jun, this suggests that if there was better early detection, these patients might have better survival rates.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x